
SUMMARY


The present disclosure comprises a novel class of heteroaromatic compounds and methods for making and using the same, said compounds having the general structure of formula (I), wherein the substituent groups are as herein defined:



(I)

These compounds are useful for the treatment of autoimmune and allergic disorders in that they exhibit good modulatory effect upon RORγ.

In one aspect, the present disclosure relates to a compound of formula (I)



(I)

wherein:

R^1 is:

–CN;

$–S(O)_nR^6$;

$–S(O)_nNR^7R^8$;

–$S(O)(NR^9)R^6$;

–$N(R^9)C(O)R^6$;

–$N(R^9)C(O)OR^6$;

–$N(R^9)S(O)_nR^6$;

–$C(O)OR^9$;

–$C(O)NR^7R^8$; or

–$C(O)R^9$; or

R^6, R^7, R^8 or R^9 of R^1 may be cyclized onto W to form a ring; and

R^2 and R^3 are each independently:

(A) –H;

(B) C_{1-3} alkyl optionally substituted with one, two or three groups selected from:

a) C_{3-6} cycloalkyl;

b) –OR^9;

c) –CN;

d) –CF_3;

e) –halo;

f) –$C(O)OR^9$;

g) –$C(O)N(R^9)_2$;

h) –$S(O)_nR^9$; and

i) –$S(O)_nNR^7R^8$; or

(C) C_{3-6} cycloalkyl;

(D) C_{3-6} heterocyclyl; or

R^2 and R^3 are taken together with the carbon to which they are attached to form a C_{3-6} carbocyclic ring; or

R^2 and R^3 are taken together with the carbon to which they are attached to form a C_{3-6} heterocyclic ring; or

R^2 or R^3 may be cyclized onto W to form a ring;

R^4 is:

(A) C_{1-6} alkyl optionally substituted with one, two or three groups selected from:

a) C_{3-6} cycloalkyl;
b) C_{3-6} heterocyclyl;
c) $-OR^9$;
d) –CN;
e) $-S(O)_nR^9$;
f) –halo; and
g) $-CF_3$; or

(B) C_{3-12} cycloalkyl optionally substituted with one, two or three groups selected from:

a) C_{1-6} alkyl;
b) $-OR^9$;
c) –CN;
d) $-S(O)_nR^9$;
e) –halo; and
f) $-CF_3$; or

(C) aryl, heteroaryl or heterocyclyl each optionally substituted with one, two or three groups selected from:

a) C_{1-6} alkyl;
b) C_{3-6}cycloalkyl;
c) $-OR^9$;
d) –CN;
e) $-S(O)_nR^9$;
f) –halo; and
g) $-CF_3$;

R^5 is aryl, heteroaryl, heterocyclyl or C_{3-12} cycloalkyl each optionally substituted with one, two or three groups selected from:

(A) C_{1-6} alkyl, C_{3-6} cycloalkyl or C_{3-6} heterocyclyl each optionally substituted with one, two or three groups selected from:

a) C_{3-6} cycloalkyl;
b) C_{3-6} heterocyclyl;
c) $-OR^9$;
d) –CN;
e) $-S(O)_nNR^7R^8$
f) $-S(O)_nR^9$;
g) –halo; and
h) $-CF_3$; or

(B) $-OR^9$;
(C) –CN;
(D) $-CF_3$;
(E) –halo;
(F) $-S(O)_nNR^7R^8$;
(G) $-S(O)_nR^9$; and
(H) $-NR^7R^8$;

W is aryl, heteroaryl, heterocyclyl, C_{3-12} cycloalkyl, or alkynyl each optionally substituted with one or two groups selected from:

a) C_{1-6} alkyl;
b) C_{3-6} cycloalkyl;
c) $-OR^9$;
d) –CN;
e) $-CF_3$;
f) –halo;
g) $-NR^7R^8$;
h) $-C(O)OR^9$; and
i) $-C(O)N(R^9)_2$;

R^6 is selected from:

(A) –OH;

(B) C_{1-6} alkyl optionally substituted with one or two groups selected from:

a) C_{3-6}cycloalkyl;
b) $-OR^9$;

c) –CN;
d) $-CF_3$; and
e) –halo;
(C) C_{3-6} cycloalkyl; and
(D) $-CF_3$;

R^7 and R^8 are independently selected from:
(A) –H;
(B) C_{1-3} alkyl optionally substituted with one or two groups selected from:
a) C_{3-6}cycloalkyl;
b) $-OR^9$;
c) –CN; and
d) –halo; and
(C) C_{3-6}cycloalkyl; or











R^7 and R^8, together with the nitrogen to which they are bonded, form a saturated ring with 3-6 carbon atoms wherein one carbon atom in said saturated ring may be optionally replaced by –O–, $-NR^9-$ or $-S(O)_n-$;











R^9 is selected from;
(A) –H;
(B) C_{1-3} alkyl optionally substituted with one or two groups selected from:
a) C_{3-6}cycloalkyl;
b) $-OR^9$;
c) –CN;
d) $-CF_3$
e) –halo; or
(C) C_{3-6}cycloalkyl; and











n is 0, 1 or 2;











or a pharmaceutically acceptable salt thereof.











In another aspect, the present disclosure relates to a compound selected from the compounds in the following table:











Example	Structure	Example	Structure
1		2	
3		4	
5		6	
7		8	
9		10	











11		12	
13		14	
15		16	
17		18	
19		20	











21		22	
23		24	
25		26	
27		28	
29		30	











31		32	
33		34	
35		36	
37		38	
39		40	











41		42	
43		44	
45		46	
47		48	
49		50	











51		52	
53		54	
55		56	
57		58	
59		60	











61		62	
63		64	
65		66	
67		68	
69		70	











71		72	
73		74	
75		76	
77		78	
79		80	











81		82	
83		84	
85		86	
87		88	
89		90	











91		92	
93		94	
95		96	
97		98	
99		100	









101		102	
103		104	
105		106	
107		108	
109		110	







111		112	
113		114	
115		116	
117		118	
119		120	







121		122	
123		124	
125		126	
127		128	
129		130	







131		132	
133		134	
135		136	
137		138	
139		140	









141		142	
143		144	
145		146	
147		148	
149		150	











151		152	
153		154	
155		156	
157		158	









159		160	
161		162	
163		164	









165		166	
167		168	
169		170	











171		172	
173		174	
175		176	











177		178	
179		180	
181		182	
183		184	











185		186	
187		188	
189		190	
191		192	
193		194	











195		196	
197		198	
199		200	
201		202	











203		204	
205		206	
207		208	
209		210	






211		212	
213		214	
215		216	
217		218	
219		220	

221		222	
223		224	
225		226	
227		228	
229		230	

231		232	
233		234	
235		236	
237		238	
239		240	

241		242	
243		244	
245		246	
247		248	
249		250	

251		252	
253		254	
255		256	
257		258	
259		260	

261		262	
263		264	
265			

or a pharmaceutically acceptable salt thereof.

In another aspect, the present disclosure relates to a pharmaceutical composition comprising a compound of formula (I) as disclosed herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

In another aspect, the present disclosure relates to a compound of formula (I) as disclosed herein, or a pharmaceutically acceptable salt thereof, for use as a medicament.

In another aspect, the present disclosure relates to the use of a compound of formula (I) as disclosed herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an autoimmune disease or allergic disorder in a patient.

DETAILED DESCRIPTION OF THE INVENTION




Definitions and Conventions Used

Terms that are not specifically defined here have the meanings that would be apparent to a person skilled in the art, in the light of the overall disclosure and the context as a whole.

As used herein, the following definitions apply, unless stated otherwise:


The use of the prefix C_{x-y}, wherein x and y each represent a natural number, indicates that the chain or ring structure or combination of chain and ring structure as a whole, specified and mentioned in direct association, may consist of a maximum of y and a minimum of x number of carbon atoms.

In general, for groups comprising two or more subgroups, unless otherwise indicated the last named subgroup is the radical attachment point, for example, the substituent "aryl-C_{1-3}-alkyl" means an aryl group which is bound to a C_{1-3}-alkyl-group, the

263		264	
265			

or a pharmaceutically acceptable salt thereof.


10. The compound according to claim 1, wherein the compound is



,

or a pharmaceutically acceptable salt thereof.


11. The compound according to claim 1, wherein the compound is



,

or a pharmaceutically acceptable salt thereof.


12. The compound according to claim 1, wherein the compound is



,

or a pharmaceutically acceptable salt thereof.


13. The compound according to claim 1, wherein the compound is



,

or a pharmaceutically acceptable salt thereof.


14. The compound according to claim 1, wherein the compound is



,


or a pharmaceutically acceptable salt thereof.

15. The compound according to claim 1, wherein the compound is




or a pharmaceutically acceptable salt thereof.

16. The compound according to claim 1, wherein the compound is




or a pharmaceutically acceptable salt thereof.

17. The compound according to claim 1, wherein the compound is



or a pharmaceutically acceptable salt thereof.


18. The compound according to claim 1, wherein the compound is



,

or a pharmaceutically acceptable salt thereof.

19. The compound according to claim 1, wherein the compound is



,

or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition comprising a compound of formula (I) according to any of the preceding claims, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

21. A compound of formula (I) according to any of claims 1 to 19, or a

pharmaceutically acceptable salt thereof, for use as a medicament.

22. Use of a compound of formula (I) according to any of claims 1 to 19, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an autoimmune disease or allergic disorder in a patient.

23. Use according to claim 22, wherein the autoimmune disease or allergic disorder is selected from rheumatoid arthritis, psoriasis, systemic lupus erythromatosis, lupus nephritis, scleroderma, asthma, allergic rhinitis, allergic eczema, multiple sclerosis, juvenile rheumatoid arthritis, juvenile idiopathic arthritis, type I diabetes, inflammatory

bowel disease, graft versus host disease, psoriatic arthritis, reactive arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, uveitis and non-radiographic spondyloarthropathy.